Stage IV Lung Cancer AJCC v8 Clinical Trials in Columbus, Ohio

12 studies are recruiting for stage iv lung cancer ajcc v8 in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    43 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06287775 on ClinicalTrials.gov

  2. Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

    This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Ohio State University Comprehensive Cancer Center

    See if you can join NCT04780568 on ClinicalTrials.gov

  3. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell sign…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Columbus Oncology and Hematology Associates Inc, Columbus, Ohio
    Locations
    603 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT04181060 on ClinicalTrials.gov

  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and …

    Stage
    Phase 3
    Ages
    70 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    324 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06096844 on ClinicalTrials.gov

  5. Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

    This phase I/II trial tests the safety, side effects and best dose of sotorasib with trastuzumab deruxtecan and how well the combination works in treating patients with KRAS G12C mutated non-small cell lung cancer that has spread to nearby tissues or lymph nodes (locally advanced) or that has sprea…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    9 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT07012031 on ClinicalTrials.gov

  6. Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

    This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (lep…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    58 in total
    Run by
    NRG Oncology

    See if you can join NCT06500481 on ClinicalTrials.gov

  7. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

    This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) an…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Mount Carmel East Hospital, Columbus, Ohio
    Locations
    454 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT05642572 on ClinicalTrials.gov

  8. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period o…

    Stage
    Phase 2
    Ages
    Any age
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    266 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT06031688 on ClinicalTrials.gov

  9. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cem…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Columbus Oncology and Hematology Associates Inc, Columbus, Ohio
    Locations
    386 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT06616584 on ClinicalTrials.gov

  10. Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

    This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    5 in total
    Run by
    Dwight Owen

    See if you can join NCT04919382 on ClinicalTrials.gov

  11. Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

    This phase Ib trial tests the safety, side effects, and best dose of the combination of vismodegib and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to o…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Dwight Owen

    See if you can join NCT06616623 on ClinicalTrials.gov

  12. PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of PBF-1129 in combination with nivolumab in treating patients with non-small cell lung cancer that has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as PBF-1129 and …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Dwight Owen

    See if you can join NCT05234307 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.